Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis.
Publication
, Journal Article
Lindner, SM; Fordyce, CB; Hellkamp, AS; Lokhnygina, Y; Piccini, JP; Breithardt, G; Mahaffey, KW; Singer, DE; Hacke, W; Halperin, JL; Hankey, GJ ...
Published in: Circulation
March 7, 2017
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Circulation
DOI
EISSN
1524-4539
Publication Date
March 7, 2017
Volume
135
Issue
10
Start / End Page
1001 / 1003
Location
United States
Related Subject Headings
- Warfarin
- Vitamin K
- Stroke
- Rivaroxaban
- Kidney Function Tests
- Kidney
- Humans
- Factor Xa Inhibitors
- Embolism
- Creatinine
Citation
APA
Chicago
ICMJE
MLA
NLM
Lindner, S. M., Fordyce, C. B., Hellkamp, A. S., Lokhnygina, Y., Piccini, J. P., Breithardt, G., … ROCKET AF Steering Committee and Investigators. (2017). Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. Circulation, 135(10), 1001–1003. https://doi.org/10.1161/CIRCULATIONAHA.116.024666
Lindner, Samuel M., Christopher B. Fordyce, Anne S. Hellkamp, Yuliya Lokhnygina, Jonathan P. Piccini, Günter Breithardt, Kenneth W. Mahaffey, et al. “Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis.” Circulation 135, no. 10 (March 7, 2017): 1001–3. https://doi.org/10.1161/CIRCULATIONAHA.116.024666.
Lindner SM, Fordyce CB, Hellkamp AS, Lokhnygina Y, Piccini JP, Breithardt G, et al. Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. Circulation. 2017 Mar 7;135(10):1001–3.
Lindner, Samuel M., et al. “Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis.” Circulation, vol. 135, no. 10, Mar. 2017, pp. 1001–03. Pubmed, doi:10.1161/CIRCULATIONAHA.116.024666.
Lindner SM, Fordyce CB, Hellkamp AS, Lokhnygina Y, Piccini JP, Breithardt G, Mahaffey KW, Singer DE, Hacke W, Halperin JL, Hankey GJ, Berkowitz SD, Nessel CC, Becker RC, Fox KAA, Patel MR, ROCKET AF Steering Committee and Investigators. Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. Circulation. 2017 Mar 7;135(10):1001–1003.
Published In
Circulation
DOI
EISSN
1524-4539
Publication Date
March 7, 2017
Volume
135
Issue
10
Start / End Page
1001 / 1003
Location
United States
Related Subject Headings
- Warfarin
- Vitamin K
- Stroke
- Rivaroxaban
- Kidney Function Tests
- Kidney
- Humans
- Factor Xa Inhibitors
- Embolism
- Creatinine